explore -WSS

explore

author：entertainment 2025-09-28 13:23:30 - browse：5791

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Generative AI mines health records to identify patients’ social needs

WSS

Stanford president to resign after investigation of research

Caregivers of transplant patients call for more support, training

New warning issued for rebooking air travel after delays, cancellations

DeSantis can now import cheaper drugs. But will Biden get credit?

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

TikTok cracks down on users posting about weight loss drugs

focus

explore

hotspot

Drug repurposing or repositioning? The language matters

How I ended up pumping milk in a bathroom stall at JPM 2024

United colonoscopy coverage change 'may cost lives,' doctors say

Celebrate National Dole Whip Day for 3 days this week at Disney

The high cost of giving birth even with insurance

New menopause drug shows promise in relief for hot flashes

ChatGPT in medicine: STAT answers readers' burning questions

Readout LOUD podcast: live from JPM 2024

Psychedelics group wrestles with new pharma identity

The SUPPORT Act is critical to fighting the opioid crisis

entertainment

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Three issues to watch in global health in 2024

Heart disease and mental health: A look at cardiac psychology

Celebrate National Dole Whip Day for 3 days this week at Disney

India sets sights on home

TikTok cracks down on users posting about weight loss drugs

hotspot

leisure time

hotspot

Wikipedia